spacer
home > ict > winter 2019 > advancing expansion
PUBLICATIONS
International Clinical Trials

Advancing Expansion

The UK has significant experience in first-in-human (FIH) clinical trials and has performed almost a quarter of the total of 2,206 FIH studies in the EU between 2005 and 2017 (Figure 1). Furthermore, the number of FIH trials conducted in the UK continues to increase; 69 out of 143 (48%) Phase 1 trials in 2016 were FIH, whereas, in 2017, this number grew to 105 out of 167 (63%) (1). The collective experience of regulators, clinical Phase 1 units, and FIH principal investigators in the last couple of decades has played a significant role in the development of guidelines for FIH/early phase clinical trials. However, two events come to the forefront of any early clinical developer’s mind in relation to the guidance issued by the EMA in this area.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Simon Hutchings has over 11 years of experience in the drug development process, including preclinical pharmacology/toxicology, Phase 1 (including first-in-human) pharmacology/ PK studies, and investigator-led Phase 2 and 3 trials. In addition to undergraduate and postgraduate qualifications in pharmacology, he also holds a Certificate in Human Pharmacology from the Faculty of Pharmaceutical Medicine at the Royal College of Physicians, UK. Simon has extensive practical experience and scientific knowledge of the design, management, and reporting of clinical development projects.
spacer
Dr Simon Hutchings
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement